| Identifying favorable-value cardiovascular health services. | |
| | |
MedLine Citation:
|
PMID: 21756013 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
OBJECTIVE: To identify cardiovascular health services with a high level of evidence to suggest that they deliver favorable value. STUDY DESIGN: Evidence synthesis using the Cost-Effectiveness Analysis Registry. METHODS: We queried the registry to identify published cost-effectiveness analyses of cardiovascular health services in the United States. In addition to searching the registry, we performed supplementary searches of published literature for cost-effectiveness studies of cardiovascular interventions that were endorsed by guidelines of national medical and scientific societies. We defined favorable value as an incremental costeffectiveness ratio of $100,000 or less per qualityadjusted life-year. RESULTS: Our initial review of cardiovascular health services in the United States revealed 174 separate peer-reviewed studies. Of those, 157 studies did not meet our inclusion criteria, leaving 17 studies for further evaluation that covered the following services with potentially high value: statins to prevent myocardial infarction (for primary and secondary prevention), screening for and treatment of high blood pressure (diuretics or beta-blockers and angiotensin-converting enzyme inhibitors in the case of diabetes) to prevent myocardial infarction and stroke, warfarin sodium and low-molecular-weight heparin to prevent pulmonary emboli, implantable cardiac defibrillators for patients at high risk of sudden death, antiplatelet drugs (aspirin and clopidogrel bisulfate) to prevent future myocardial infarction, beta-blockers for patients who have had myocardial infarction, warfarin to prevent future stroke in persons with nonvalvular atrial fibrillation, and percutaneous procedures to relieve claudication symptoms. CONCLUSION: We describe a new way of synthesizing cost-effectiveness evidence for use by consumers, payers, and other decision makers. |
| | |
Authors:
|
R Scott Braithwaite; Sherry M Mentor |
Related Documents
:
|
20424993 - Relaxin: review of biology and potential role in treating heart failure. 9821003 - The peripheral syndrome of heart failure: the overlooked aspects. 2835963 - Myocardial hypertrophy: the effect of sodium and the role of sympathetic nervous system... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: The American journal of managed care Volume: 17 ISSN: 1936-2692 ISO Abbreviation: Am J Manag Care Publication Date: 2011 Jun |
Date Detail:
|
Created Date: 2011-07-15 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9613960 Medline TA: Am J Manag Care Country: United States |
Other Details:
|
Languages: eng Pagination: 431-8 Citation Subset: H |
Affiliation:
|
Section of Value and Comparative Effectiveness, Division of General Internal Medicine, NYU School of Medicine, 423 E 23rd St, 15th Floor, New York, NY 10010. E-mail: scott.braithwaite@nyumc.org. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Better continuity of care reduces costs for diabetic patients.
Next Document: Shared medical appointments in a residency clinic: an exploratory study among Hispanics with diabete...